Biocon Ltd
BIOCONBSE 532523PharmaceuticalsMkt cap ₹60,445 Cr
Whole group, including subsidiaries — the figures companies headline.
Revenue · Q1 FY27
₹4,336 Cr
YoY +10.0%QoQ -4.0%
Net profit · Q1 FY27
₹137 Cr
YoY +53.4%QoQ -31.1%
Net margin · Q1 FY27
3.1%
+0.9 pts vs Q1 FY26
Net profit · FY26
₹369 Cr
YoY -74.2%
Quarterly results
| ₹ Cr | Q1 FY27 Apr–Jun 2026 | Q4 FY26 Jan–Mar 2026 | Q3 FY26 Oct–Dec 2025 | Q2 FY26 Jul–Sep 2025 | Q1 FY26 Apr–Jun 2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 4,336 | 4,517 | 4,173 | 4,296 | 3,942 | +10.0% |
| Other income | 54.50 | 52.50 | 117 | 93.00 | 79.70 | -31.6% |
| Total income | 4,391 | 4,569 | 4,290 | 4,389 | 4,022 | +9.2% |
| Profit before tax | 128 | 248 | 0.00 | 171 | 96.90 | +31.7% |
| Tax | -9.20 | 48.90 | -16.00 | 38.50 | 7.70 | -219.5% |
| Net profit | 137 | 199 | -51.80 | 133 | 89.20 | +53.4% |
| Net margin | 3.1% | 4.4% | -1.2% | 3.1% | 2.3% |
Annual results
| ₹ Cr | FY26 Apr 2025–Mar 2026 | FY25 Apr 2024–Mar 2025 | FY24 Apr 2023–Mar 2024 | FY23 Apr 2022–Mar 2023 | FY22 Apr 2021–Mar 2022 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 16,927 | 15,262 | 14,756 | 11,174 | 8,184 | +10.9% |
| Other income | 343 | 1,208 | 866 | 376 | 213 | -71.7% |
| Total income | 17,270 | 16,470 | 15,621 | 11,550 | 8,397 | +4.9% |
| Profit before tax | 448 | 1,887 | 1,609 | 1,064 | 1,190 | -76.3% |
| Tax | 79.10 | 457 | 227 | 254 | 212 | -82.7% |
| Net profit | 369 | 1,429 | 1,298 | 643 | 772 | -74.2% |
| Net margin | 2.2% | 9.4% | 8.8% | 5.8% | 9.4% |
BIC's take
We haven't covered Biocon Ltd yet. Browse our sector reports →
Source: BSE filings · Data as of 2 Oct 2026, 6:57 pm IST· ₹ crore unless stated. Covers BSE 500 companies only. Consolidated figures include subsidiaries; standalone is the parent company alone. Growth is shown only against a positive base. Not investment advice — check the company's full filing before acting.